Historical Valuation
Oncolytics Biotech Inc (ONCY) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.69. The fair price of Oncolytics Biotech Inc (ONCY) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：0.97
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Oncolytics Biotech Inc (ONCY) has a current Price-to-Book (P/B) ratio of 1218.14. Compared to its 3-year average P/B ratio of 128.90 , the current P/B ratio is approximately 845.04% higher. Relative to its 5-year average P/B ratio of 78.48, the current P/B ratio is about 1452.21% higher. Oncolytics Biotech Inc (ONCY) has a Forward Free Cash Flow (FCF) yield of approximately -18.22%. Compared to its 3-year average FCF yield of -22.91%, the current FCF yield is approximately -20.49% lower. Relative to its 5-year average FCF yield of -21.25% , the current FCF yield is about -14.29% lower.
P/B
Median3y
128.90
Median5y
78.48
FCF Yield
Median3y
-22.91
Median5y
-21.25
Competitors Valuation Multiple
AI Analysis for ONCY
The average P/S ratio for ONCY competitors is 0.94, providing a benchmark for relative valuation. Oncolytics Biotech Inc Corp (ONCY.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for ONCY
1Y
3Y
5Y
Market capitalization of ONCY increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ONCY in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ONCY currently overvalued or undervalued?
Oncolytics Biotech Inc (ONCY) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.69. The fair price of Oncolytics Biotech Inc (ONCY) is between NaN to NaN according to relative valuation methord.
What is Oncolytics Biotech Inc (ONCY) fair value?
ONCY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Oncolytics Biotech Inc (ONCY) is between NaN to NaN according to relative valuation methord.
How does ONCY's valuation metrics compare to the industry average?
The average P/S ratio for ONCY's competitors is 0.94, providing a benchmark for relative valuation. Oncolytics Biotech Inc Corp (ONCY) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Oncolytics Biotech Inc (ONCY) as of Jan 10 2026?
As of Jan 10 2026, Oncolytics Biotech Inc (ONCY) has a P/B ratio of 1218.14. This indicates that the market values ONCY at 1218.14 times its book value.
What is the current FCF Yield for Oncolytics Biotech Inc (ONCY) as of Jan 10 2026?
As of Jan 10 2026, Oncolytics Biotech Inc (ONCY) has a FCF Yield of -18.22%. This means that for every dollar of Oncolytics Biotech Inc’s market capitalization, the company generates -18.22 cents in free cash flow.
What is the current Forward P/E ratio for Oncolytics Biotech Inc (ONCY) as of Jan 10 2026?
As of Jan 10 2026, Oncolytics Biotech Inc (ONCY) has a Forward P/E ratio of -4.38. This means the market is willing to pay $-4.38 for every dollar of Oncolytics Biotech Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Oncolytics Biotech Inc (ONCY) as of Jan 10 2026?
As of Jan 10 2026, Oncolytics Biotech Inc (ONCY) has a Forward P/S ratio of 0.00. This means the market is valuing ONCY at $0.00 for every dollar of expected revenue over the next 12 months.